Bhatt AS, Luo N, Solomon N, et al. - Researchers focused on the treatment patterns and outcomes for patients with type 2 diabetes and heart failure (HF) based on geography (North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific). Participants were individuals who took part in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) and had HF at baseline and a documented ejection fraction (EF) (N = 1,591; 10.8%). The link between geographic region and the primary outcome of all-cause mortality (ACM) or hospitalization for HF (hHF) in addition to ACM alone was assessed using Cox models. EF ≥ 40% was present in 1,267 (79.6%) patients. Across all regions, a high use of beta-blocker (83%) and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (86%) was reported in patients with EF < 40%. Findings revealed the existence of significant variation in the clinical characteristics and results of HF patients across the regions in TECOS. Lower risk-adjusted ACM/hHF was observed in patients from Eastern Europe vs those in North America, driven by those with EF ≥ 40%.